Experiences with

Luteinizing hormone releasing hormone (LHRH) agonist

They noted "key takeaways" to include: **Transdermal estradiol is as effective as LHRH agonist and there is no detriment in terms of prostate cancer outcomes or overall survival in starting androgen suppression with transdermal estradiol **Transdermal estradiol provides choice about expected side effects

I got, with great difficulty a DEXA scan one month after starting LHRH agonist goserelin. No one told me I needed it, and given my polio as a kid I probably was likely to already have some osteoporosis risk at 73. And yes I had lumber osteoporosis and osteopenia in my hip and neck of femur.

[i]This recent research paper in Nature is potentially ground-breaking for the understanding of essential mechanisms involved with bone health. It's findings are related to hormonal changes during the start of mid-pregnancy lactation and early newborn nurturing that could possibly lay the foundation

ADT’s impact on Muscle and Fat October 23, 2023 Standard ADT with either LHRH agonist or antagonist drugs (like Lupron or Firmagon, respectively) cause a loss of lean muscle mass and weight gained as fat. Those are among the most common side effects of ADT.

New study below [1]. Men with PCa have a greater risk of death from cardiovascular [CV] events, and androgen deprivation therapy [ADT] further increases that risk. The study looked at ADT drugs that target gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. The drugs were Degarelix

Hello :) For anyone based in the UK (London if it's face to face), do you have a great dietician / nutritionist that you can recommend? I have endometriosis and IBS. I'd also like to lose some weight and generally have a better lifestyle / relationship with food / improve my energy levels. I've just

agonist.

Starting LHRH agonist on the first day of radiation therapy, as in the EORTC 22863 study, should be the standard of care when treating locally advanced prostate cancer.

Starting LHRH agonist on the first day of radiation therapy, as in the EORTC 22863 study, should be the standard of care when treating locally advanced prostate cancer.

Satterfield's office regarding his LHRH agonist. Is this all or where to from here??????????

All patients were treated using 400 mg testosterone cypionate intramuscularly every 28 days, together with continuous LHRH agonist therapy. Clinical-grade DNA sequencing was obtained using commercially available assays.

Briefly, patients who had been identified as mCRPC (adenocarcinoma of the prostate with systemic metastatic disease despite castrate levels of testosterone (<50 ng/dl) due to orchiectomy or luteinising hormone-releasing hormone (LHRH) agonist, undergoing ADT (gonadotropin-releasing hormone (GnRH) agonist

The new study analyzed the US electronic medical records of 45,059 men with prostate cancer receiving a luteinizing hormone releasing hormone (LHRH) agonist and antagonist injections. The team examined the rate of MACE within 6 months and 1 year of ADT initiation.

This was a multi-center, single-arm, open-label phase 2 trial of men with mCRPC who received testosterone cypionate 400mg intramuscular (BAT) every 28 days and nivolumab 480mg IV every 28 days, during which time LHRH agonist treatment was continued.

One week ago I recieved Diphereline 3,75 mg first injection. And one month ago i had lap enfometriosi excision operation. So far I feel actualy grate.. I never could imagine.. that I would feel like yung person again.. (Im still 32).. full with energy. Im worried abaut Diphereline! I heard that it

The GETUG-AFU 16 trial demonstrated that 6 months of luteinizing hormone releasing hormone (LHRH) agonist treatment during salvage RT significantly reduced clinical progression (5-year progression-free survival, 80.0 vs. 62.0%). c.

In the recent Lancet article about the PATCH trial, men on LHRH agonist for 6 months had a mean increase of 0.14 mmol/l, with a range of 0.04 - 0.24. My increase is 2.5 units i.e. tenfold that of the person with the largest increase in the group.

., Chahin, R. and Alibhai, S.M. (2015), Phase II, randomised, double‐blind, placebo‐controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH‐agonist therapy.

I’m writing this post with a preamble that these are my opinions, and I cannot prove any of them, nor am I trying to prove them. So, please read these conclusions with this information in mind. I believe that information about tE2 is difficult to uncover because in the US, the medical industrial complex

If T is above target, physicians should ensure adherence to ADT dosing schedules, prescribe a different formulation of LHRH agonist/antagonist therapy or offer surgical castration.